Reiterer Florian, Polterauer Philipp, Schoemaker Michael, Schmelzeisen-Redecker Guenther, Freckmann Guido, Heinemann Lutz, Del Re Luigi
1 Institute for Design and Control of Mechatronical Systems, Johannes Kepler University, Linz, Austria.
2 Roche Diabetes Care Deutschland GmbH, Mannheim, Germany.
J Diabetes Sci Technol. 2017 Jan;11(1):59-67. doi: 10.1177/1932296816662047. Epub 2016 Sep 25.
There is a need to assess the accuracy of continuous glucose monitoring (CGM) systems for several uses. Mean absolute relative difference (MARD) is the measure of choice for this. Unfortunately, it is frequently overlooked that MARD values computed with data acquired during clinical studies do not reflect the accuracy of the CGM system only, but are strongly influenced by the design of the study. Thus, published MARD values must be understood not as precise values but as indications with some uncertainty.
Data from a recent clinical trial, Monte Carlo simulations, and assumptions about the error distribution of the reference measurements have been used to determine the confidence region of MARD as a function of the number and the accuracy of the reference measurements.
The uncertainty of the computed MARD values can be quantified by a newly introduced MARD reliability index (MRI), which independently mirrors the reliability of the evaluation. Thus MARD conveys information on the accuracy of the CGM system, while MRI conveys information on the uncertainty of the computed MARD values.
MARD values from clinical studies should not be used blindly but the reliability of the evaluation should be considered as well. Furthermore, it should not be ignored that MARD does not take into account the key feature of CGM sensors, the frequency of the measurements. Additional metrics, such as precision absolute relative difference (PARD) should be used as well to obtain a better evaluation of the CGM performance for specific uses, for example, for artificial pancreas.
需要评估连续血糖监测(CGM)系统在多种用途下的准确性。平均绝对相对差(MARD)是用于此目的的首选指标。遗憾的是,人们常常忽略,用临床研究期间获取的数据计算出的MARD值并不能仅反映CGM系统的准确性,还会受到研究设计的强烈影响。因此,已发表的MARD值不应被理解为精确值,而应被视为具有一定不确定性的指标。
来自近期一项临床试验的数据、蒙特卡洛模拟以及关于参考测量误差分布的假设,已被用于确定作为参考测量数量和准确性函数的MARD置信区间。
计算出的MARD值的不确定性可以通过新引入的MARD可靠性指数(MRI)进行量化,该指数独立反映评估的可靠性。因此,MARD传达了关于CGM系统准确性的信息,而MRI传达了关于计算出的MARD值不确定性的信息。
临床研究中的MARD值不应盲目使用,还应考虑评估的可靠性。此外,不应忽视MARD未考虑CGM传感器的关键特征,即测量频率。还应使用其他指标,如精确绝对相对差(PARD),以便更好地评估CGM系统在特定用途(例如人工胰腺)下的性能。